Literature DB >> 10547588

Expression of potentially oncogenic HHV-8 genes in an EBV-negative primary effusion lymphoma occurring in an HIV-seronegative patient.

F Cobo1, S Hernández, L Hernández, M Pinyol, F Bosch, J Esteve, A López-Guillermo, A Palacín, M Raffeld, E Montserrat, E S Jaffe, E Campo.   

Abstract

Primary effusion lymphoma (PEL) is a novel lymphoproliferative disorder associated with human herpesvirus 8 (HHV-8) infection. Most PELs develop in HIV-seropositive individuals and are nearly always positive for Epstein-Barr virus (EBV), a finding which obscures the role of HHV-8 in lymphomagenesis. However, rare EBV-negative PEL cases occurring in HIV-seronegative patients have been reported, suggesting that HHV-8 may be pathogenetic by itself. To investigate whether HHV-8 may contribute to PEL development in the absence of EBV, the expression of seven potentially oncogenic HHV-8 open reading frames (ORFs) (ORF72/viral cyclin D, ORF16/viral bcl-2, ORF74/viral G-protein coupled receptor, ORFK2/viral IL-6, ORFK13/viral FLICE inhibitory protein, ORFK9/viral interferon regulatory factor, and ORFK1, equivalent to the gene encoding herpesvirus saimiri transforming protein) was assessed by reverse transcriptase-polymerase chain reaction (RT-PCR) in an EBV-negative PEL presenting in an HIV-negative patient. RNA transcripts were demonstrated for the seven HHV-8 genes, and this was confirmed by hybridization to specific oligonucleotide probes. The expression of potentially oncogenic HHV-8 genes in this HIV-, EBV-negative PEL case suggests that HHV-8 may induce malignant transformation of B-lymphocytes through different molecular pathways in the absence of EBV infection. Copyright 1999 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  1999        PMID: 10547588     DOI: 10.1002/(SICI)1096-9896(199910)189:2<288::AID-PATH419>3.0.CO;2-F

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  9 in total

Review 1.  Aggressive B-cell lymphomas: a review of new and old entities in the WHO classification.

Authors:  Elaine S Jaffe; Stefania Pittaluga
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2011

2.  Successful eradication of relapsed primary effusion lymphoma with high-dose chemotherapy and autologous stem cell transplantation in a patient seronegative for human immunodeficiency virus.

Authors:  Jong-Ho Won; Seung-Hyo Han; Sang-Byung Bae; Chan-Kyu Kim; Nam-Su Lee; Kyu-Taeg Lee; Sung-Kyu Park; Dae-Sik Hong; Dong-Wha Lee; Hee-Sook Park
Journal:  Int J Hematol       Date:  2006-05       Impact factor: 2.490

3.  Primary effusion lymphoma with skin involvement.

Authors:  S Inoue; T Miyamoto; T Yoshino; I Yamadori; Y Hagari; O Yamamoto
Journal:  J Clin Pathol       Date:  2006-11       Impact factor: 3.411

Review 4.  The histological classification of diffuse large B-cell lymphomas.

Authors:  Yi Xie; Stefania Pittaluga; Elaine S Jaffe
Journal:  Semin Hematol       Date:  2015-01-17       Impact factor: 3.851

Review 5.  Cancers associated with human gammaherpesviruses.

Authors:  Kwun Wah Wen; Linlin Wang; Joshua R Menke; Blossom Damania
Journal:  FEBS J       Date:  2021-09-18       Impact factor: 5.622

Review 6.  The histological and biological spectrum of diffuse large B-cell lymphoma in the World Health Organization classification.

Authors:  Madhu P Menon; Stefania Pittaluga; Elaine S Jaffe
Journal:  Cancer J       Date:  2012 Sep-Oct       Impact factor: 3.360

Review 7.  EBV-driven B-cell lymphoproliferative disorders: from biology, classification and differential diagnosis to clinical management.

Authors:  Chi Young Ok; Ling Li; Ken H Young
Journal:  Exp Mol Med       Date:  2015-01-23       Impact factor: 8.718

Review 8.  Classic KSHV/HHV-8-positive Primary Effusion Lymphoma (PEL): A Systematic Review and Meta-Analysis of Case Reports.

Authors:  Ilaria Cozzi; Giovanni Rossi; Emma Rullo; Valeria Ascoli
Journal:  Mediterr J Hematol Infect Dis       Date:  2022-03-01       Impact factor: 2.576

9.  An unusual case of Primary Effusion Lymphoma with aberrant T-cell phenotype in a HIV-negative, HBV-positive, cirrhotic patient, and review of the literature.

Authors:  Charitini Nepka; Dimitrios Kanakis; Maria Samara; Andreas Kapsoritakis; Spyridon Potamianos; Maria Karantana; Georgios Koukoulis
Journal:  Cytojournal       Date:  2012-06-29       Impact factor: 2.091

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.